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~The natural history of liver disease in Cystic Fibrosis 
R. Bhattacharjee 2 , S. Schibli 1 , J. Rose 2 , E. Tullis 3, R Durie 2 , L. Ellis 2 , T. Kovesi 4, 
M. Corey 2. 1 University Children ~' Hospital Berne, Switzerlan& 2Hospital for 
Sick Children, 3St. Michael X' Hospital, Toronto; 4Children ~' Hospital of Eastern 
Ontario, Ottawa, Canada 
Aims: To describe the natural history of clinically significant CF related liver 
disease (CFRLD), defined as evidence of multilobular cirrhosis and/or portal 
hypertension. 
Methods: Retrospective identification of patients with CFRLD (> 1 yr: 1986~ 004) 
using the Toronto Database and several search strategies. Chart review to define 
natural history and interventions. 
Results: 53 patients were identified to have CFRLD; 52 charts were available for 
review. Median CFRLD diagnosis age was 13.2yrs, with 81% diagnosed under 
the age of 18. Mean duration of follow-up data available: 10.6yrs (±6.6 years). 
Complications of CFLRD included, hypersplenism in 23 patients (44%) and variceal 
bleeding in 14 (27%). Twelve patients required esophageal banding, shunting or 
sclerotherapy. Persistent hypoalbuminemia w s seen in 6 patients (12%). Of 46 pa- 
tients with routine coagulation studies, 3 patients (7%) had a fixed coagulopathy. 
Seven patients (13%) developed persistent hyperbilirubinemia. Six patients (12%) 
had developed hepatocellular failure at 16, 25, 28, 44, 45 and 52yrs of age 
respectively. Three patients underwent liver transplantation; all have survived for 
3yr, 5yr and 10yrs respectively. Two others are listed for liver transplantation. 
There were 15 deaths with a median age of mortality of 27.3 yrs (range: 17.5 52). 
Only one died from complications of liver failure. 
Conclusions: Portal Hypertension with variceal bleeding and hypersplenism, is the 
most frequent long-term complication of CFRLD. The vast majority of patients 
with CFLRD maintain adequate hepatocellular function for many years (without 
requiring a liver transplant). 
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l~  Coinheritance of Gilbert syndrome associated UGTIA1 mutation 
increases the risk of gallstones in CF 
M. Barker 1, H. Wasmuth 2, H. Keppler 3, F. Lammert 3. 1Dept. of Pediatrics, 
2Dept. of Medicine III, University Hospital Aachen, 3Dept. of Internal Medicine L 
University Hospital Bonn, Germany 
Aims: Malabsorption of bile acids, augmented intestinal bilirubin uptake and 
hyperbilirubinbilia h ve been proposed as key factors in the formation of pigment 
gallstones in patients with CE We tested the hypothesis that the common UGT1A1 
promoter mutation that is associated with Gilbert syndrome is an additional 
lithogenic risk factor. 
Methods: 52 patients with established CF (age 20.4±8.6yrs, 27 females) were 
sonografically investigated for the presence of gallbladder stones. Serum levels of 
total and direct bilirubin were measured, and UGT1A1 genotype was assessed by 
direct sequencing of PCR products. 
Results: Patients with gallstones (n 9) were significantly more likely to carry 
at least one UGT1A1 mutation (Odds ratio 7.3 compared to stone-free CF sub- 
jects, p 0.042) and displayed significantly higher levels of unconjugated bilirubin 
(p 0.002). Homoygosity for the A(TA)7 TAA allele was detected in 5 and 
heterozygosity in 26 subjects, and only one patient with gallstones did not carry a 
mutated UGT 1A 1 allele. 56% of stone-harboring patients and 38% of those without 
evidence of gallstones had a current reatment with ursodesoxycholic a id. 
Conclusion: Among CF patients, coinheritance of the Gilbert UGT1A1 allele in- 
creases the risk of gallstone formation. This genetic association supports the current 
concept of gallstone formation in CF and suggests that 'hyperbilirubinbilia' through 
hereditary or exogenous factors may contribute to lithogenesis n CF patients. 
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Objective: In  a subset of  382 CF patients attendillg our centre between 1989 and 2005 continuous 
treatment w i th  UDCA (20mg/kg/d)  was rigorously ilfitiated i f  one or more serum liver ellzymes 
(ALT, AST, ?-GT, GLDH)  were elevated ~>1.5 t imes above tile upper normal  l imit over a period o f  
~>6 months.  
Methods: In  a retrospective analysis, liver enzyme values, weight  for height and FEV1 were extracted 
f rom tile charts. CF patients f rom tile t ime between 1975 and 1989, when no UDCA was available, 
were used for comparison. 
Patients: UDCA was introduced ill 98 patients at a mean age o f  14.8 years (0.6 36). Tile mean 
duration of  observation was 7.2 years (1 15). 
Results: 
Age (years) (n) AST ALT y-GT GLDH Thro Weight FEV1 
(U/l) (U/l) (U/l) (U/l) (G/l) for %pred 
[22] [23] [25] [2.8] [475] Height 
Before UDCA 14.8±8.2 98 27.4 32.8 34.8 10.0 292 101.8 82.8 
±25.3 ±32.6 ±49.1 ±10.4 ±92 ±12.2 ±21.7 
5 years on UDCA 18.6±7.2 79 18.1" 17.5" 17.9" 3.0* 289 104.4 83.4 
±11.7 ±8.3 ±19.3 ±3.5 ±104 ±12.2 ±23.5 
10 years on UDCA 23.1 ±5.3 39 17.3" 22.3 27.9 3.6* 259 106.3 82.9 
±8.3 ±14.2 ±38.3 ±3.8 ±104 ±15.5 ±23.6 
15 years on UDCA 27.3±4.2 10 16.3 25.1 33.3 3.0 238 104.5 84.0 
±7.9 ±18.7 ±26.7 ±3.2 ±102 ±6.6 ±17.9 
Mean ± standard eviation, [upper limit of reference range], Mann-Whitney Test, * significant p < 0.05. 
In  tile UDCA group, severe liver disease wi th  portal hypertension and thrombopenia <80G/1 
developed ill two patients (18 year old boy, 24 year old woman).  In  tile historic group without  UDCA,  
9 patients developed severe liver disease, at a mean age o f  7.6 (2 15) years, 3.9 (2~4.7) years after 
tile first elevation of  liver enzymes. 
Conclusion: UDCA delays severe liver disease wi th  portal hypertension ill CE  Nevertheless, ill face 
o f  slightly increased values after 10 or 15 years, normal isat ion of  liver enzymes may be transitorily. 
Interestingly, this subgroup of  patients bad a stable FEV1.  
